Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. We believe that better cell therapies start with better cells. To produce better cell therapies, we apply our proprietary iPSC product platform to create multiplexed-engineered, clonal master iPSC lines having preferred biological properties.
Clonal master iPSC lines can be used as a renewable cell source to manufacture cell therapy products that can be delivered off-the-shelf to treat many patients. Our cells of interest are the cells of the immune system. And our cell therapy product candidate pipeline is comprised of natural killer (NK) cell and T-cell product candidates.
Better Cells for Better Therapies®
